ERBB2 and neoplasm: All patientsshowed good tolerability of RPH at all stages of dynamic follow-up.Additionally, at a dose of 1,000 μg, the drug exhibited enhancedpharmacokinetic properties two hours after administration, along with superiorbreast tumor separation rates contingent upon HER2/neu status.